Josh Kohn-Lindquist, The Motley Fool
4 min read
David Weill, a Director at TransMedics Group, Inc. (NASDAQ:TMDX), purchased 1,336 shares of common stock on Sept. 11, 2026. SEC Form 4 filing
Transaction summary
Transaction value based on SEC Form 4 weighted average purchase price ($81.63); post-transaction value based on Sept. 11, 2026, market close ($82.18).
Key questions
-
How did this transaction affect the director’s total equity stake?
The acquisition of 1,336 shares, representing 9% of the shares held prior to the filing, increased the total direct holdings to 16,392 shares. -
What is the current market valuation of the insider’s position?
Based on the Sept. 14, 2026, market close price of $85.86, David Weill’s 16,392 shares are valued at ~$1.4 million. -
What performance context surrounded the acquisition?
The purchase was executed as the stock recorded a one-year return of -30% through the Sept. 11, 2026, transaction date. -
What are the primary operations of TransMedics Group?
The company is a commercial-stage medical technology enterprise that focuses on organ transplant therapy through its Organ Care System, which is designed to monitor and optimize donor organs.
Company Overview
Company Snapshot
-
TransMedics Group, Inc. develops and commercializes the Organ Care System (OCS), a portable medical device that perfuses, optimizes, and continuously monitors donor organs to improve transplant outcomes and expand the donor organ pool.
-
The company generates revenue through the sale of OCS devices and related consumables, service agreements, and licensing arrangements with transplant centers and healthcare systems globally.
-
TransMedics serves transplant centers, hospitals, and organ procurement organizations in North America and internationally, targeting institutions performing heart, lung, and liver transplantation procedures.
TransMedics Group is a commercial-stage medical technology enterprise with a market capitalization of $2.7 billion and TTM revenues of $668.5 million, demonstrating significant scale in the organ transplantation technology sector. The company’s Organ Care System represents a differentiated approach to donor organ preservation, using proprietary perfusion technology to recreate near-physiological conditions and extend the viability window of organs. This innovation positions TransMedics as a critical enabler of expanded criteria donor utilization and improved transplant outcomes, providing a competitive advantage in addressing the substantial global shortage of viable donor organs.
